Renal Dysfunction after Living-Donor Liver Transplantation: Experience with 500 Cases
Table 2
Profile of both groups at one year after liver transplantation.
Variable
Normal kidney function at one year
Chronic kidney disease at one year
P Value
Group I (n = 380)
Group II (n = 33)
Age, years
51 (46-55) (24-63)
49 (45.5-55) (43-63)
0.642
Gender male:female, n
341:39
30:3
0.831
Body mass index, kg/m2
28.4 (25.6-31.1) (17.6-43.74)
27.9 (26.0-31.2) (21.3-34.63)
0.807
Serum creatinine before Tx
0.8 (0.6-1.0) (0.5-2.2)
0.7 (0.6-0.9) (0.5-1.2)
0.197
Serum albumin before Tx, g/dl
2.9 (2.5-3.3) (1.5-5.5)
2.7 (2.5-3.1) (1.5-3.9)
0.237
Serum total bilirubin before Tx, mg/dl
2.9 (1.8-4.3) (0.3-25)
2.6 (1.65-4.35) (0.5-10.5)
0.741
INR before Tx
1.6 (1.3-1.9) (1-4.9)
1.5 (1.35-2.1) (1.1-3.19)
0.951
MELD score before Tx
15 (13-18) (6-40)
16 (12.5-20) (9-34)
0.291
GRWR
1.008 (0.9-1.2) (0.77-1.8)
0.805 (0.8-0.9) (0.77-1.35)
< 0.0005
Preoperative renal impairment, n (%)
13 (3.42105)
6 (18.18181)
< 0.0005
HRS before Tx, n (%)
12 (3.2)
5 (15.2)
0.001
CI, minutes
35 (23-50) (10-175)
35 (25.5-54.5) (16-120)
0.349
WI, minutes
44.5 (34-66.75) (18-175)
49 (40-65) (31-95)
0.306
Hepatic vein anastomoses, n (%)
1
258 (67.9)
18 (54.5)
2
70 (18.4)
10 (30.3)
0.267
3
37 (9.7)
5 (15.2)
4
14 (3.7)
0 (0.0)
5
1 (0.3)
0 (0.0)
Portal vein anastomoses, n (%)
1
372 (97.9)
33 (100.0)
0.400
2
8 (2.1)
0 (0.0)
Hepatic artery anastomoses, n (%)
1
371 (97.6)
33 (100.0)
0.371
2
9 (2.4)
0 (0.0)
Intraoperative blood loss, ml
5400 (3700-7600) (550-16000)
8500 (7000-9750) (1700-14000)
< 0.0005
Fresh frozen plasma, n (%)
0
235 (61.8)
14 (42.4)
1-6 units
48 (12.6)
5 (15.2)
0.072
More than 6 units
97 (25.5)
14 (42.4)
Operative time, minutes
575 (430-660) (300-960)
800 (775-855) (400-940)
< 0.0005
Immunosuppression in ICU
Tacrolimus
244 (64.2)
20 (60.6)
Cyclosporin
85 (22.4)
8 (24.2)
0.916
Others
51 (13.4)
5 (15.2)
AKI in ICU by creatinine criteria, n (%)
119 (31.315789)
9 (27.27272)
0.630
AKI in ICU by urine output criteria, n (%)
44 (11.57894)
5 (15.15151)
0.543
Biliary complications, n (%)
28 (7.4)
2 (6.1)
0.781
Acute rejection, n (%)
37 (9.7)
2 (6.1)
0.488
Hemodialysis, n (%)
3 (0.8)
0 (0)
0.608
Renal impairment at one month, n (%)
70 (18.4)
8 (24.2)
0.412
Survival, months
70 (45.25-96) (12-156)
70 (52.5-98) (12-156)
0.358
Data were expressed as median (interquartile range, IQR 25-75) (minimum-maximum) unless otherwise stated. Statistically significant values are in bold. Tx, transplantation; INR, international normalized ratio; MELD, model for end stage liver disease; GRWR, graft-to-recipient weight ratio; HRS, hepatorenal syndrome; CI, cold ischemia; WI, warm ischemia; ICU, intensive care unit; AKI, acute kidney injury.
